Advances and challenges in developing andrographolide and its analogues as cancer therapeutic agents
Copyright © 2019 Elsevier Ltd. All rights reserved..
Andrographolide (AGP), a naturally occurring bioactive compound, has been investigated as a lead compound in cancer drug development. Its multidimensional therapeutic effects have raised interest among medicinal chemists, which has led to extensive structural modification of the compound, resulting in analogues with improved pharmacological and pharmaceutical properties. Nevertheless, the analogues with the improved properties need to be rigorously studied to identify drug-like lead compounds. We scrutinised articles published from 2012 to 2018, to objectively provide opinions on the mechanisms of action of AGP and its analogues, as well as their potential as viable anticancer drugs. Preclinical and clinical data, along with the extensive medicinal chemistry efforts, indicate the compounds are potential anticancer agents with specific value in treating recalcitrant cancers such as pancreatic and lung cancers.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Drug discovery today - 24(2019), 9 vom: 15. Sept., Seite 1890-1898 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Soo, Hon Liong [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
410105JHGR |
|---|
| Anmerkungen: |
Date Completed 15.06.2020 Date Revised 15.06.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.drudis.2019.05.017 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM297717405 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM297717405 | ||
| 003 | DE-627 | ||
| 005 | 20231225092611.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.drudis.2019.05.017 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0992.xml |
| 035 | |a (DE-627)NLM297717405 | ||
| 035 | |a (NLM)31154065 | ||
| 035 | |a (PII)S1359-6446(18)30221-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Soo, Hon Liong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Advances and challenges in developing andrographolide and its analogues as cancer therapeutic agents |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.06.2020 | ||
| 500 | |a Date Revised 15.06.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Andrographolide (AGP), a naturally occurring bioactive compound, has been investigated as a lead compound in cancer drug development. Its multidimensional therapeutic effects have raised interest among medicinal chemists, which has led to extensive structural modification of the compound, resulting in analogues with improved pharmacological and pharmaceutical properties. Nevertheless, the analogues with the improved properties need to be rigorously studied to identify drug-like lead compounds. We scrutinised articles published from 2012 to 2018, to objectively provide opinions on the mechanisms of action of AGP and its analogues, as well as their potential as viable anticancer drugs. Preclinical and clinical data, along with the extensive medicinal chemistry efforts, indicate the compounds are potential anticancer agents with specific value in treating recalcitrant cancers such as pancreatic and lung cancers | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Diterpenes |2 NLM | |
| 650 | 7 | |a andrographolide |2 NLM | |
| 650 | 7 | |a 410105JHGR |2 NLM | |
| 700 | 1 | |a Quah, Shun Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Sulaiman, Ibrahim |e verfasserin |4 aut | |
| 700 | 1 | |a Sagineedu, Sreenivasa Rao |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, Jonathan Chee Woei |e verfasserin |4 aut | |
| 700 | 1 | |a Stanslas, Johnson |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug discovery today |d 1998 |g 24(2019), 9 vom: 15. Sept., Seite 1890-1898 |w (DE-627)NLM095449159 |x 1878-5832 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2019 |g number:9 |g day:15 |g month:09 |g pages:1890-1898 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.drudis.2019.05.017 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2019 |e 9 |b 15 |c 09 |h 1890-1898 | ||